Introduction
The development of molecularly targeted therapies has had a dramatic impact on the treatment of breast cancer. Clinical studies have shown that endocrine therapies targeting the estrogen receptor (ER) pathway (Kurebayashi, 2007) and antagonists of the HER2 receptor tyrosine kinase (Hudis, 2007) are effective in the treatment of early and late stage breast cancers. This has lead to the development of therapeutic agents targeting additional signaling pathways involved in promoting tumor growth such as the insulin-like growth factor (IGF) pathway.
The IGF system consists of ligands (IGF-I and IGF-II), receptors (IGF-IR and IGF-IIR), and binding proteins (IGFBP1-6) that regulate normal growth and development. There is also substantial evidence that IGF signaling plays an important role in a variety of human cancers including breast cancer (Pollak et al., 2004) . The physiological actions of IGF-I and IGF-II are mediated by IGF-IR, a cell surface tyrosine kinase. Ligand-induced activation of IGF-IR leads to a series of phosphorylation events that activate the PI3-K and MAPK signaling pathways resulting in cellular proliferation and inhibition of apoptosis (Surmacz, 2000; LeRoith and Roberts, 2003) .
Several lines of evidence suggest that the IGF pathway is involved in breast cancer. Epidemiological studies have shown that high serum levels of IGF-I are associated with increased risk of developing breast cancer (Hankinson et al., 1998; Renehan et al., 2004) . In biopsies of breast cancer tissue, increased mRNA expression of IGF-I (Yee et al., 1989) and IGF-II (Yee et al., 1988; Paik, 1992; Singer et al., 1995; Giani et al., 1996) has been detected in stromal cells surrounding malignant breast epithelium. Also, IGF-IR is frequently overexpressed in breast cancer (Surmacz, 2000) with tyrosine kinase activity of IGF-IR increased as much as 40-fold in tumor cells compared with normal breast tissue (Resnik et al., 1998) . Upregulation of IGF-IR signaling has also been implicated in mediating resistance of breast cancer cells to chemotherapeutic agents, radiation, and targeted therapies such as Tamoxifen (Parisot et al., 1999) and Herceptin (Lu et al., 2001) .
A direct role for IGF signaling in mammary tumorigenesis has been demonstrated in a number of transgenic mouse models. Overexpression of IGF-I (Hadsell et al., 2000) or IGF-II (Bates et al., 1995; Pravtcheva and Wise, 1998) in the mammary epithelium results in tumor development, albeit with long latency. Recently, mammary specific overexpression of a constitutively active IGF-IR (Carboni et al., 2005) or wildtype IGF-IR (Jones et al., 2007) has been shown to induce rapid tumor formation by 2 months of age.
A number of strategies have been developed to interfere with IGF-IR signaling, some of which have recently entered the clinical trial stage (Haluska et al., 2007; Rowinsky et al., 2007) . These include agents that reduce ligand availability such as anti-IGF antibodies, anti-sense, and RNA interference molecules to reduce IGF-IR expression and small molecule inhibitors that target IGF-IR tyrosine kinase activity. Pre-clinical studies performed in vitro and/or in nude mice using these strategies have demonstrated that targeting IGF-IR directly or indirectly can inhibit breast cancer cell growth (Arteaga et al., 1989; Chernicky et al., 2000; Burtrum et al., 2003; Mitsiades et al., 2004; Goetsch et al., 2005; Divisova et al., 2006; Feng et al., 2006; Haluska et al., 2007; Rowinsky et al., 2007) . Although these experiments certainly illustrate the therapeutic potential of inhibiting IGF-IR, there are a number of limitations of these studies that should be considered. Firstly, in vitro experiments or xenograft models may not accurately reflect the in vivo environment found in human breast cancers. Secondly, the use of cell lines does not take into account the fact that human breast cancers are heterogeneous and contain multiple cell types that can influence response to therapy. Finally, the consequence of long-term inhibition of IGF-IR on breast cancer cells has not been examined. Breast cancer patients who initially respond to targeted therapies often develop resistance resulting in recurrent tumor growth (Ali and Coombes, 2002; Nahta and Esteva, 2007) . Thus, a critical goal of research involving anti-IGF-IR therapies is to determine whether resistance will occur and the molecular pathways that govern tumor escape from IGF-IR inhibition.
To address these questions, we used a doxycyclinedependent mouse model (MTB-IGFIR) in which IGF-IR expression can be tightly regulated in the mammary epithelium through the addition and removal of doxycycline from the animal's food. We have shown earlier that IGF-IR overexpression in MTB-IGFIR mice results in the rapid development of multiple mammary tumors (Jones et al., 2007) . In this paper, we describe the consequence of eliminating IGF-IR transgene expression in established mammary tumors. We observed three tumor fates (i) tumors regressed to a non-palpable state and did not resume growth, (ii) tumors initially regressed to a nonpalpable state and resumed growth, or (iii) tumors only partially regressed (or did not regress at all) and resumed growth. Interestingly, of the tumors that resumed growth, some of the tumors reactivated the IGF-IR transgene in a doxycycline-independent manner, whereas the other tumors grew in the absence of high IGF-IR expression and were classified as IGF-IR-independent tumors. These IGF-IR-independent tumors displayed features of an epithelial to mesenchymal transition (EMT) and contained elevated levels of transcriptional repressors of Ecadherin including Snail, Slug, Zeb1, and Twist. These results show that breast tumor cells can become independent of their initiating oncogene thus suggesting that some of the tumors will develop resistance to therapies targeting a single oncogene. (Figures 1a and b) . Of the three tumors that did not fully regress, two of these tumors eventually resumed growth in the absence of doxycycline. As MTB-IGFIR transgenic mice develop multiple mammary tumors, mice often presented with several smaller mammary tumors (that is, o293 mm 3 ). These tumors were also measured after doxycycline withdrawal. One hundred percent of these tumors (101 of 101) were found to regress to a non-palpable state after removal of doxycycline.
Results

Elimination
Next, we examined whether larger tumors possessed a similar dependence on IGF-IR transgene expression. We hypothesized that by allowing tumors to grow to a larger size before transgene downregulation, the tumors would be less dependent on the initiating oncogene. Doxycycline was removed from 31 mice in which the average size of the largest primary tumor was approximately 2000 mm 3 (range, 1414-2456 mm 3 ). Only 21/31 (68%) of these larger tumors regressed to a nonpalpable state, with an average time to regression of 71 ± 31 days (Figures 1c and d) . Of the 10 tumors that failed to regress to a non-palpable state, 8 partially regressed (7 eventually resumed growth in the absence of doxycycline) and 2 of the tumors displayed no noticeable tumor regression. Collectively, these results indicate that the majority of IGF-IR-induced mammary tumors remain dependent upon IGF-IR signaling for maintenance of the neoplastic phenotype; however, a subset of tumors became independent of doxycycline-mediated IGF-IR transgene expression.
Tumor regression is associated with decreased proliferation and increased apoptosis To examine the early events of tumor regression, we isolated tumors from mice that had been removed from doxycycline for 24, 48, 72, and 96 h. After 24 h of doxycycline removal, the overall architecture of tumors remained intact and consisted of solid sheets of epithelial cells with organized intervening stromal tissue Recurrent tumor formation in the absence of doxycycline presumably represents a true tumor recurrence as each recurrent tumor appeared at the site of the original primary tumor, and we have yet to observe tumor formation in MTB-IGFIR mice in the absence of doxycycline. Also, we have shown earlier that injection of a primary MTB-IGFIR mammary tumor cell line, RM11A, into the mammary fat pad of doxycycline treated wild-type mice results in the rapid development of mammary tumors (Jones et al., 2008) . To test whether RM11A tumors regress and recur, doxycycline was removed from 12 animals bearing RM11A tumors 10 mm in largest diameter (range of tumor volume 293-590 mm 3 , mean tumor volume 368 mm 3 ). Similar to what was observed in MTB-IGFIR mice, 9/12 tumors regressed to a non-palpable state and 8 of these mice spontaneously developed tumor recurrence within an average of 27 days (range, 21-93 days) after regression to a non-palpable state ( Figure 3c ). As RM11A cells were injected into nontransgenic animals, these recurrent tumors almost certainly developed from cells within the primary RM11A tumor.
Doxycycline-independent growth is associated with IGF-IR-dependent or IGF-IR-independent mechanisms
Tumors that failed to regress to a non-palpable state or regressed then recurred were classified as doxycyclineindependent tumors (DITs). Histological analysis of DITs revealed that these tumors can be categorized into two main categories (i) tumors that resemble IGF-IRinduced primary tumors (Figure 4a ) and were composed primarily of cuboidal epithelial cells (Figure 4b ) and (ii) tumors that were composed of elongated spindle-shaped cells (Figure 4c) . A small percentage of DITs contained a mixture of epithelial and spindle cells, exhibited squamous differentiation or were found to be fluidfilled cysts upon examination (Table 2) . Immunohistochemistry revealed that 100% of DITs that had an epithelial morphology expressed high levels of IGF-IR (Figure 4e ), whereas all spindle-cell tumors expressed low levels of IGF-IR (Figure 4f ).
Approximately 33% of MTB-IGFIR mice bearing primary IGF-IR-induced tumors contain metastatic lesions in the lungs (Figure 4g ). Examination of lung tissue from mice bearing DITs revealed that lung metastases were present in 4/9 mice bearing DITs with an epithelial morphology (Figure 4h ). Immunohistochemistry confirmed that these lesions also overexpressed IGF-IR (Figure 4k ). In contrast, only 1/8 mice harboring a DIT with a spindle-cell morphology exhibited lung metastasis (Figure 4i ). In agreement with a lack of IGF-IR expression in spindle-cell DITs, this metastatic lesion did not express IGF-IR ( Figure 4l ).
As subsets of DITs were indistinguishable from primary tumors in both histology and level of IGF-IR expression, we next examined whether these DITs had re-activated the human IGF-IR transgene in a doxycycline-independent manner. To address this, we used primers that detect the human IGF-IR cDNA sequence. Importantly, these primers have been used to distinguish mice carrying the IGF-IR transgene and wild-type mice and thus do not amplify the endogenous mouse IGF-IR transcript (Jones et al., 2007) . Both primary and epithelial DITs expressed high levels of human IGF-IR, whereas spindle DITs expressed low levels of human IGF-IR as determined by RT-PCR (Figure 4m ). Therefore, tumor cells can bypass their dependency on doxycycline either by reactivating the IGF-IR pathway or using an alternative mechanism for tumor growth.
IGF-IR independence is accompanied by an EMT
Histologically, mammary tumors induced by IGF-IR overexpression in MTB-IGFIR mice often resemble those initiated by erbB2 and are composed primarily of solid sheets of epithelial cells that stain positive for cytokeratin 8 and 18. We have also found that some advanced IGF-IR-induced tumors resemble Wnt pathway initiated tumors and contain areas with considerable stromal elements and cytokeratin 5 and 14 positive cells (Jones et al., 2007) . However, we have yet to observe tumors that would be classified histologically as spindle-cell tumors. For that reason, DITs that are composed primarily of spindle-shaped cells suggests that IGF-IR-induced tumors have undergone an EMT before resuming growth. Characteristic features of EMT include the loss of epithelial cell markers such as cytokeratin 8 and E-cadherin and the upregulation of mesenchymal cell markers including vimentin. Consistent with this, western blot analysis and immunohistochemistry revealed that the DIT spindle-cell tumors expressed low or undetectable levels of E-cadherin ( Figure 5a ) and cytokeratin 8 (Figure 5d ) but did contain increased levels of vimentin (Figure 5g ) in comparison to primary tumors and DITs that had reactivated IGF-IR (Figures 5a, b, c, e and f) . Regression of IGF-IR-induced mammary tumors RA Jones et al
Next, we used quantitative RT-PCR and profiled the expression of a set of genes that have been implicated in EMT and are known transcriptional repressors of E-cadherin (Figure 6a ). We detected a significant increase in mRNA levels of the zinc-finger transcription factors Snail and to a lesser degree Slug in spindle-cell DITs compared with primary IGF-IR-induced tumors. In addition, we also found that EMT tumors contained significantly increased mRNA levels of Zeb1 and Twist.
We have reported earlier that MTB-IGF-IR tumors contain increased levels of downstream IGF-IR signaling molecules including the phosphorylated forms of Akt, Erk1/Erk2, and Stat3 compared with normal mammary tissue (Jones et al., 2007) . To determine whether escape from IGF-IR dependence was associated with alterations in these pathways, we examined their protein expression levels in primary tumors and DITs (Figure 6b ). Western blot analysis revealed a reduction in activated Akt levels but a consistent increase in total Akt levels in the spindle DITs compared with primary tumors and epithelial DITs. The level of activated Erk1/ Erk2 was variable between the tumor groups, whereas all tumors were found to express comparable levels of total Erk, phosphorylated Stat3, and total Stat3.
Discussion
A number of pharmaceutical companies are designing antibodies or small molecule inhibitors that specifically disrupt IGF-IR function. The rationale for targeting the IGF-IR stems largely from cell culture experiments that show the importance of IGF-IR signaling in promoting proliferation, inhibiting apoptosis, and rendering breast cancer cells resistant to radiation and chemotherapy. However, considerably less is known about the function of IGF-IR in mammary tumorigenesis in vivo. Thus, the experiments described in this paper were designed to determine (i) whether mammary tumors induced by IGF-IR overexpression remain dependent on this oncogene for survival and continued growth, (ii) does IGF-IR suppression result in tumor regression and if so is tumor regression transient or stable, and (iii) in the event that tumor regression is not sustained what are the molecular pathways linked with IGF-IR independence.
Using our inducible mouse model of breast cancer, therapeutic targeting of IGF-IR was simulated through withdrawal of the IGF-IR transgene inducing agent, doxycycline, from mice with established mammary tumors. Doxycycline withdrawal resulted in suppression of IGF-IR transgene expression and rapid regression of a majority of the tumors; however, regression to a nonpalpable state occurred more frequently and more rapidly in tumors approximately 500 mm 3 than in tumors approximately 2000 mm 3 . This finding suggests that as tumors increase in size, they acquire additional genetic alterations that allow them to become independent of the initiating oncogene, IGF-IR. Regression rates observed with the 500 mm 3 tumors in the MTB-IGF-IR transgenics were similar to those observed in mammary tumors induced by Wnt1 (Gunther et al., 2003) or constitutively active ErbB2 (Moody et al., 2002) but considerably higher than regression rates observed in c-Myc-induced mammary tumors (D'Cruz et al., 2001; Boxer et al., 2004) . The effect of tumor size on regression rates was not explored in these other doxycycline inducible mammary tumor models. Therefore, our data suggests that tumor size may predict oncogene dependence and thus targeting the IGF-IR may prove more effective in earlier stage disease than in large, advanced breast tumors.
In examining the cellular mechanisms involved in tumor regression after IGF-IR transgene suppression, a reduction in staining for PCNA and an increase in TUNEL staining was clearly observed in tumors 72 h after doxycycline withdrawal. This supports our earlier findings that short-term doxycycline withdrawal (24-72 h) results not only in the rapid downregulation of the IGF-IR transgene but also leads to reduction in the levels of cyclin D1 and activated Akt (Jones et al., 2008) . Thus, the early events of tumor regression after IGF-IR suppression involves downregulation of the cell-cycle regulator cyclin D1 and the loss of the pro-survival effects of Akt leading to reduced proliferation and increased apoptosis of tumor cells.
The primary limitation of most therapies is tumor recurrence after an initial reduction in tumor size. This phenomenon is generally thought to arise from a small subset of tumor cells that are intrinsically resistant to the therapeutic strategy used (Aguirre-Ghiso, 2007) . Although most of the tumor cells succumb to therapy (chemotherapy, radiation, or molecular targeting) leading to a decrease in tumor size, the resistant subpopulation of cells will eventually proliferate and result in the formation of a recurrent tumor. This recurrent tumor is largely resistant to the initial therapy as the cells giving rise to the resistant tumor are intrinsically resistant. To evaluate whether tumor regression after IGF-IR transgene suppression was stable or transient, a cohort of 37 animals with tumors approximately 500 mm 3 in size that had regressed to a non-palpable state after doxycycline withdrawal were observed for 8 months in the absence of doxycycline supplementation. Of the 37 mice, 6 of the mice (16%) developed mammary tumors in the same mammary gland as the initial tumor 53 days (range, 21-83 days) after regressing to a non-palpable state. Although some of these tumors re-activated the IGF-IR transgene in the absence of doxycycline, slightly less than half of these recurrent tumors did not express high levels of IGF-IR. As these tumors express only low levels of IGF-IR, they would likely be resistant to any additional rounds of IGF-IR targeted therapy. Therefore, these studies show that although tumor formation is induced through a single genetic alteration (IGF-IR overexpression), sub-populations of cells within the tumor can become independent of this initiating genetic alteration, suggesting that resistance to IGF-IR targeting agents in humans is highly probable in at least some cases. The development of resistance to molecularly targeted therapy is not completely surprising considering patients treated with trastuzumab (antibody that targets the HER2 receptor) initially display tumor regression but frequently present with trastuzumab resistant tumors within a year of treatment (Slamon et al., 2001) . A subset of tumors that recurred in the absence of doxycycline expressed high levels of IGF-IR and maintain an epithelial morphology. Using primers specific for human IGF-IR, RT-PCR demonstrated that these tumors had reactivated the human IGF-IR transgene. A recent study has shown that doxycyclineindependent activation of transgenes can arise through somatic mutations within the reverse-tetracycline transactivator transgene (Podsypanina et al., 2008) . It is also possible that chromosomal re-arrangements occur such that transgene expression becomes regulated by an endogenous promoter rather than the tetracycline responsive elements. The mechanism of doxycyclineindependent transgene expression in our model is currently under investigation.
Interestingly, the tumors that recurred independent of IGF-IR transgene re-expression displayed a morphological change from an epithelial phenotype to one that was associated with EMT. Mammary tumor escape from the initiating oncogene, accompanied by EMT, has been reported in similar doxycycline inducible breast cancer models. In these models, recurrent tumors displaying features of EMT were found to contain increased mRNA levels of the E-cadherin transcriptional repressors Snail (Moody et al., 2005; Debies et al., 2008) and to a lesser degree Slug (Moody et al., 2005) . In addition, Snail itself was shown to play a causal role in promoting recurrence of fully regressed erbB2-induced tumors (Moody et al., 2005) . In agreement with these studies, we also found that Snail and Slug mRNA levels were upregulated in our EMT tumors. In addition, we also detected an increase in transcript levels of Zeb1 and Twist, both of which have been shown to directly repress E-cadherin transcription and induce EMT in breast cancer cells in vitro (Eger et al., 2005; Vesuna et al., 2008) . Whether Zeb1 and Twist are causally linked to tumor recurrence in a similar manner to Snail will require further investigation.
Accumulating evidence suggests that EMT plays a critical role in the early stages of malignant tumor progression (Peinado et al., 2007) . However, we observed lung metastases in only 1/8 mice harboring a DIT with a spindle-cell morphology, whereas lung metastases were identified in 4/9 mice bearing DITs that had an epithelial morphology and had reactivated the IGF-IR transgene. A number of possible explanations may account for our conflicting observation that tumor cells exhibiting an EMT phenotype are less metastatic compared with their epithelial counterparts. As IGF-IR has been shown to promote the invasive and migratory properties of a number of human cancer cell lines including breast cancer cells (Dunn et al., 1998) it is possible that loss of IGF-IR renders tumor cells incapable of metastases. It is also possible that the spindle-shaped tumor cells are in fact invasive but loss of IGF-IR results in reduced survival of tumor cells once they have disseminated into the circulation. However, a more likely explanation is that IGF-IR-independent spindle-cell tumor cells have undergone a permanent EMT. Although EMT appears to be involved in the initial stages of metastases, secondary nodules from epithelial tumors typically resemble the phenotype of the primary tumor suggesting that the reverse process, a mesenchymal-to-epithelial transition, is required for the final stages of the metastatic cascade (Chaffer et al., 2006; Hugo et al., 2007) . Thus, the reduction in metastases may be due to the inability of IGF-IRindependent tumor cells to re-differentiate and colonize the secondary site.
In summary, this study provides important insight into the potential benefits and pitfalls of therapeutic strategies targeting IGF-IR for the treatment of breast cancer. Similar to other targeted agents, our results suggest that a proportion of the tumor will be inherently resistant or will develop resistance to anti-IGF-IR strategies. These limitations will have to be overcome through the use of combination with conventional therapies or simultaneous targeting of multiple molecular targets before IGF-IR targeted therapy (and likely other molecular targets) will be effective clinically.
Materials and methods
Mice
Generation of MTB-IGFIR transgenic mice and the primary MTB-IGFIR mammary tumor cell line, RM11A, has been described earlier (Jones et al., 2007 (Jones et al., , 2008 . To induce transgene expression, standard rodent chow was replaced with rodent chow containing 2 g/kg of doxycycline (Bio-Serv, Frenchtown, NJ, USA). Maximum and minimum tumor diameters were measured weekly using digital calipers, and tumor volume was calculated using the formula V ¼ axb 2 /2. Tumors that were non-palpable on two consecutive occasions were considered to be fully regressed. All mice were maintained following the guidelines of the Canadian Council on Animal Care.
Immunohistochemistry and TUNEL assay Immunohistochemistry was performed as described earlier (Linnerth et al., 2005) . Primary antibodies included a 1:100 dilution of anti-IGF-IR (R&D systems Inc, Minneapolis, MN, USA), anti-cyotkeratin 8 (Fitzgerald Industries International Inc., Concord, MA, USA), anti-Vimentin and a 1:3000 dilution of PCNA (Sigma, St Louis, MO, USA). TUNEL assay was performed using the In Situ Cell Death Detection Kit (Roche, Laval, QC, Canada). Briefly, 5 mm paraffin sections were dewaxed and rehydrated, treated with Proteinase K (20 mg/ml) for 15 min at room temperature, rinsed twice with PBS, incubated with TUNEL reaction mixture (TdT enzyme and reaction buffer) for 1 h at 37 1C, followed by signal conversion as per manufacturer's instructions with DAB substrate (Sigma, St Louis, MO, USA). Sections were then counterstained with hematoxylin and mounted with Permount (Fisher Scientific, Whitby, ON, Canada)
Western blotting
Western blotting and protein visualization was performed as described earlier (Linnerth et al., 2005; Jones et al., 2007) . Primary antibodies included 1:1000 dilutions of anti-IGF-IR (R&D), anti-phospho-IGF-IR, anti-E-cadherin, anti-phosphoAkt (Ser473), anti-phospho-Erk1/Erk2, Erk1/Erk3, anti-phospho-Stat3, Stat3 (Cell Signal Technology, Danvers, MA, USA), and anti-GAPDH (Santa Cruz Technologies, Santa Cruz, CA, USA).
RNA isolation, cDNA synthesis, and real-time RT-PCR Total RNA was extracted using TRIZOL reagent (Invitrogen, Burlington, ON, Canada) followed by the ArrayGrade Total RNA Isolation Kit following the manufacturer's instructions (SuperArray, Frederick, MD, USA). Contaminating genomic DNA was removed using Turbo DNA-Free reagent (Ambion, Austin, TX, USA) and first strand cDNA was synthesized from 1 mg of total RNA using oligo-(dT) 12-18 primers and SuperScript II Reverse Transcriptase following the manufacturer's protocols (Invitrogen, Burlington, ON, Canada). Realtime PCR was performed using a Lightcycler instrument (Roche Molecular Biochemicals, Laval, QC, Canada) and consisted of 20 ml-reaction mixtures using 1 ml cDNA, 1X Platinum qPCR Supermix-UDG with BSA (Invitrogen) and 0.5 mM of each primer. The PCR parameters were as follows: UDG incubation (50 1C for 2 min), denaturation (95 1C for 2 min), followed by 45 cycles of PCR (95 1C, 10 s, 60 1C, 10 s, 72 1C, 10 s). Melting curve analysis confirmed the presence of a single PCR product and agarose gel electrophoresis was performed to verify PCR product size. Reaction efficiency of each primer set was determined using 10-fold serial dilutions of a representative cDNA sample and expression of each gene was then normalized to GAPDH mRNA levels with efficiency correction using Relative Quantification Software (Roche Molecular Biochemicals, Laval, QC, Canada). Primer sequences for Snail and Slug are available in the RTPRimerDB database (Pattyn et al., 2006) and sequences for additional primer sets have been published earlier: IGF-IR (Jones et al., 2007) Twist (Yang et al., 2004) , Zeb1 and TGF-b (Kato et al., 2007) , and GAPDH (Nichols and Kirby, 2008) .
Statistics
The log-rank test was used to determine statistical significance between two survival curves, and the Student's t-test was used for the comparison of two means.
